Drug & Supplement Interactions

Antineoplastons + Nilutamide

Brand names of Nilutamide

  • Nilandron
  • Anandron

Medically reviewed by

Also reviewed by the HelloPharmacist Editorial Team

Updated July 2026Details about this page

AI is used only to summarize verified clinical information, never the open internet. Our AI policy

The Bottom Line No Known Interaction

We found no known interaction between Antineoplastons and Nilutamide in our sources.

This also applies to Nilandron and Anandron, brand names of nilutamide.

Still Worth Knowing

  • Shared side effects: Although there is no interaction, both can cause some of the same side effects. Taken together, those side effects might add up, and a new symptom can be harder to pin on one or the other.
See the Full Interaction Report

Ask a Question About This Combination

Ask in your own words about taking Antineoplastons with Nilutamide. The answer comes from this page’s own records.

Try:

AI answers from this page’s interaction records and our own drug and supplement information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist. How we use AI

Interaction Report

Antineoplastons and Nilutamide Interaction Check

No Known Interaction Found

We did not find a documented interaction between Nilutamide and Antineoplastons in our sources. This does not guarantee that the combination is completely free of risk — there is often limited research on supplements and herbal products, especially around drug interactions.

How We Checked

Why No Interaction Is Listed for Nilutamide

Antineoplastons has no interaction record with any drug in our interaction database, so this rests on missing data, not on a study that found nothing.

Still wondering about combining Antineoplastons and Nilutamide? Ask Dr. Brian Staiger, PharmD, BCPS directly ›
Know someone taking this combination? Share

Before You Combine Them

Taking Antineoplastons and Nilutamide Together

What to Watch For

Side Effects Antineoplastons and Nilutamide Have in Common

13 side effects show up for both Antineoplastons and Nilutamide.

  • Each has separately been linked to the effects below. Taken together, they might add up: the same side effect from two sources might be more likely or stronger. No study of the two together says by how much.
  • If one turns up, it can be harder to tell which one is behind it, so tell your pharmacist you take both.
  • 2 of them are worth acting on rather than waiting out, marked below.
  • Chest pain / Raised blood pressure Worth Acting On Additional detail

    Antineoplastons

    Intravenously, antineoplaston A5 has been associated with palpitations at doses up to 153 mg/kg daily. A 71 year-old male bladder cancer patient experienced chest pressure and irregular heartbeat after receiving intravenous antineoplaston A5 58 mg/kg/day for 5 days. Use of intravenous antineoplaston AS2-1, up to 160 mg/kg daily for over 2 years, has been associated with mild hypertension.

    Source: , the clinical database we license.

    5 references cited
    1. 25608. Burzynski SR, Kubove E, Burzynski B. Phase I clinical studies of antineoplaston A5 injections. Drugs Exp Clin Res 1987;13 Suppl 1:37-43.
    2. 25622. Burzynski SR, Kubove E, Burzynski B. Phase I clinical studies of antineoplaston A5 injections. Drugs Exp Clin Res 1987;13 Suppl 1:37-43.
    3. 25604. Tsuda H, Hara H, Eriguchi N, et al. Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients. Kurume Med J 1995;42(4):241-249. PubMed
    4. 25619. Burzynski SR, Burzynski B, Mohabbat MO. Toxicology studies on antineoplaston AS2-1 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:25-35.
    5. 25607. Burzynski SR, Kubove E. Phase I clinical studies of antineoplaston A3 injections. Drugs Exp Clin Res 1987;13 Suppl 1:17-29.

    Nilutamide

    Source: Nilutamide’s

    It lists this side effect in its Adverse Reactions section.

    Read Nilutamide’s label on DailyMed ›
  • Anemia Worth Acting On Additional detail

    Antineoplastons

    Orally and intravenously, decreased bone marrow activity has been reported for patients treated with chemotherapy along with antineoplaston A10 or antineoplaston AS2-1; however, this effect has not been observed for patients treated with these antineoplastons without chemotherapy.

    Intravenously, antineoplastons A10 and AS2-1 have been associated with anemia and lowered white blood cell counts in patients with brain t…

    Source: , the clinical database we license.

    6 references cited
    1. 20101. Burzynski SR, Mohabbat MO, Burzynski B. Human toxicology studies on oral formulation of Antineoplaston A10. Drugs Exp Clin Res 1984;10(12):891-909.
    2. 25604. Tsuda H, Hara H, Eriguchi N, et al. Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients. Kurume Med J 1995;42(4):241-249. PubMed
    3. 25603. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 2003;4(2):91-101. PubMed
    4. 25611. Burzynski SR, Weaver RA, Janicki T, et al. Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1. Integr Cancer Ther 2005;4(2):168-177. PubMed
    5. 99814. Burzynski SR, Janicki TJ, Weaver RA, Burzynski B. Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma. Integr Cancer Ther. 2006 Mar;5(1):40-7. PubMed
    6. 25623. Kumabe T, Tsuda H, Uchida M, et al. Antineoplaston treatment for advanced hepatocellular carcinoma. Oncol Rep 1998;5(6):1363-1367. PubMed

    Nilutamide

    Source: Nilutamide’s

    It lists this side effect in its Adverse Reactions section.

    Read Nilutamide’s label on DailyMed ›
  • Tiredness reported in 17.6% of FDA reports for Nilutamide Additional detail

    Antineoplastons

    Orally and intravenously, headache, fatigue, sleepiness, ringing in the ears, and numbness have been reported for patients treated with antineoplastons A10 and AS2-1. Dizziness has also been noted for some patients treated with oral antineoplaston A10 or intravenous antineoplaston A3.

    Source: , the clinical database we license.

    6 references cited
    1. 25593. Buckner JC, Malkin MG, Reed E, et al. Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc 1999;74(2):137-145. PubMed
    2. 25601. Burzynski SR, Conde AB, Peters A, et al. A retrospective study of antineoplastons A10 and AS2-1 in primary brain tumors. Clin Drug Invest 1999;18(1):1-10.
    3. 25603. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 2003;4(2):91-101. PubMed
    4. 25610. Burzynski SR, Weaver RA, Lewy RI, et al. Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report. Drugs R D 2004;5(6):315-326. PubMed
    5. 25620. Burzynski SR, Kubove E. Toxicology studies on antineoplaston A10 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:47-55.
    6. 20101. Burzynski SR, Mohabbat MO, Burzynski B. Human toxicology studies on oral formulation of Antineoplaston A10. Drugs Exp Clin Res 1984;10(12):891-909.

    Orally and intravenously, antineoplastons AS2-1 and A10 have been associated with peripheral edema. Swelling of joints, muscle and joint pain, muscle contractions in the throat, weakness, and fatigue have been reported for patients treated with antineoplastons A2, AS2-1, AS2-5, and/or A10.

    Source: , the clinical database we license.

    5 references cited
    1. 25604. Tsuda H, Hara H, Eriguchi N, et al. Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients. Kurume Med J 1995;42(4):241-249. PubMed
    2. 25624. Burzynski SR. Toxicology studies on antineoplaston AS2-5 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:17-24.
    3. 25603. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 2003;4(2):91-101. PubMed
    4. 25620. Burzynski SR, Kubove E. Toxicology studies on antineoplaston A10 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:47-55.
    5. 25621. Burzynski SR, Kubove E. Initial clinical study with antineoplaston A2 injections in cancer patients with five years' follow-up. Drugs Exp Clin Res 1987;13 Suppl 1:1-11.

    Nilutamide

    Source: Nilutamide’s

    It lists this side effect in its Adverse Reactions section. Voluntary reports to the FDA mention it too.

    Read Nilutamide’s label on DailyMed ›
  • Stomach upset / Stomach pain Additional detail

    Antineoplastons

    Orally, nausea, vomiting, upset stomach, abdominal pain, and excessive flatulence has been reported for patients with neoplastic disease treated with antineoplaston A10 100-149 mg/kg/day for up to 149 days.

    Source: , the clinical database we license.

    2 references cited
    1. 20101. Burzynski SR, Mohabbat MO, Burzynski B. Human toxicology studies on oral formulation of Antineoplaston A10. Drugs Exp Clin Res 1984;10(12):891-909.
    2. 25620. Burzynski SR, Kubove E. Toxicology studies on antineoplaston A10 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:47-55.

    Nilutamide

    Source: Nilutamide’s

    It lists this side effect in its Adverse Reactions section.

    Read Nilutamide’s label on DailyMed ›
  • Fever Additional detail

    Antineoplastons

    Adverse effects to antineoplastons have been reported in several small clinical studies. It is not clear how common these reactions are, or if they occur more frequently than with placebo. Since many patients taking antineoplastons have been diagnosed with serious illnesses, such as advanced cancers, it is not clear if these effects resulted from the illnesses themselves or were caused by antineoplastons.

    Source: , the clinical database we license.

    5 references cited
    1. 20101. Burzynski SR, Mohabbat MO, Burzynski B. Human toxicology studies on oral formulation of Antineoplaston A10. Drugs Exp Clin Res 1984;10(12):891-909.
    2. 25604. Tsuda H, Hara H, Eriguchi N, et al. Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients. Kurume Med J 1995;42(4):241-249. PubMed
    3. 25620. Burzynski SR, Kubove E. Toxicology studies on antineoplaston A10 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:47-55.
    4. 25621. Burzynski SR, Kubove E. Initial clinical study with antineoplaston A2 injections in cancer patients with five years' follow-up. Drugs Exp Clin Res 1987;13 Suppl 1:1-11.
    5. 25603. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 2003;4(2):91-101. PubMed

    Intravenously, fever has been reported in patients receiving 6 months of treatment with A10 (11.3 grams/kg daily) and AS2-1 (0.4 grams/kg daily).

    Source: , the clinical database we license.

    2 references cited
    1. 25603. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 2003;4(2):91-101. PubMed
    2. 25619. Burzynski SR, Burzynski B, Mohabbat MO. Toxicology studies on antineoplaston AS2-1 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:25-35.

    Nilutamide

    Source: Nilutamide’s

    It lists this side effect in its Adverse Reactions section.

    Read Nilutamide’s label on DailyMed ›
  • Swelling Additional detail

    Antineoplastons

    Recorded for Antineoplastons in the same Natural Medicines adverse-effect record shown under Tiredness above.

    Nilutamide

    Source: Nilutamide’s

    It lists this side effect in its Adverse Reactions section.

    Read Nilutamide’s label on DailyMed ›
  • Dizziness Additional detail

    Antineoplastons

    Recorded for Antineoplastons in the same Natural Medicines adverse-effect record shown under Tiredness above.

    Nilutamide

    Source: Nilutamide’s

    It lists this side effect in its Adverse Reactions section.

    Read Nilutamide’s label on DailyMed ›
  • A skin rash Additional detail

    Antineoplastons

    Intravenously, mild maculopapular allergic-type rash has been noted in patients receiving antineoplaston AS2-1, up to 160 mg/kg daily for up to 2.4 years. During 6 months of intravenous bolus injections of A10 (11.3 grams/kg daily) and AS2-1 (0.4 grams/kg daily), three cases of skin rash were reported for patients with recurrent brain stem glioma.

    Source: , the clinical database we license.

    4 references cited
    1. 25619. Burzynski SR, Burzynski B, Mohabbat MO. Toxicology studies on antineoplaston AS2-1 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:25-35.
    2. 25603. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 2003;4(2):91-101. PubMed
    3. 25623. Kumabe T, Tsuda H, Uchida M, et al. Antineoplaston treatment for advanced hepatocellular carcinoma. Oncol Rep 1998;5(6):1363-1367. PubMed
    4. 25624. Burzynski SR. Toxicology studies on antineoplaston AS2-5 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:17-24.

    Nilutamide

    Source: Nilutamide’s

    It lists this side effect in its Adverse Reactions section.

    Read Nilutamide’s label on DailyMed ›

Showing the 10 most notable of 13 shared effects — ranked by how unusual each one is, not just whether both lists mention it.

Reported for Antineoplastons but not commonly for Nilutamide: an irregular heartbeat, ringing in the ears, a fast or pounding heartbeat and low blood sugar.

Note: Effects for Nilutamide come from the Adverse Reactions section of its FDA label; effects for Antineoplastons come from the Natural Medicines adverse-effect record, quoted above. Where a percentage is shown, it is the share of 74 voluntary FDA FAERS reports for Nilutamide that mention that effect — a reporting proportion, not an incidence rate and not evidence the drug caused it. The two sources word some effects differently, so we match them by meaning.

If You Decide to Take Both
  • Add one new thing at a time, and note the date you started it.
  • A start date turns “I’ve been feeling off” into something a pharmacist can work with.
  • Do not stop a prescribed medicine on your own.
  • Check with your pharmacist or doctor before changing any medicine or supplement, especially if you take several or have an ongoing health condition.
Overlapping Uses

Using Antineoplastons for the Same Condition as Nilutamide

Why This Matters

  • The same goal. Nilutamide is prescribed for prostate cancer, and Antineoplastons has been studied for it too.
  • It might help, or it might go too far. If Antineoplastons does work for it, the two effects might add up. That might mean better control, or it might go further than intended.
  • Tell your prescriber. A graded use is not a treatment, so do not stop or replace Nilutamide on your own. If you take Antineoplastons for the same reason, your prescriber may want to keep a closer eye on how Nilutamide is working.

Nilutamide is a prescription medicine with approved uses on its FDA label. Antineoplastons is a supplement: here is what researchers have looked at it for, and how strong that evidence is.

From the FDA Label

Nilutamide Is Prescribed For

Nilutamide tablets are used together with surgical castration (removal of the testicles) to treat metastatic prostate cancer — prostate cancer that has spread to other parts of the body (Stage D2). It is not used alone; it works as part of this combined treatment approach.

Read the rest of what Nilutamide is prescribed for

For the best results, treatment with nilutamide should begin on the same day as surgical castration, or the day after.

From the Natural Medicines Research Record

Antineoplastons Has Been Studied For

Studied for prostate cancer, with too little research to rate it yet.

See what the research shows
  • Prostate cancer Studied, Not Established
    Read what the research shows

    Preliminary clinical research shows that administering AS2-1 along with diethylstilbestrol 0.01-0.02 mg/kg daily to patients with prostate cancer results in complete remission in 14% of patients, partial remission in 22% of patients, disease stabilization in 50% of patients, and disease progression in 14% of patients. This research suffers from poor study design and the lack of a comparator group.

    1 reference cited
    1. 20102. Burzynski SR, Kubove E, Burzynski B. Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1. Drugs Exp Clin Res 1990;16(7):361-369.

The grades and the research summaries are from the Natural Medicines database, which grades evidence from “Effective” down to “Insufficient Reliable Evidence To Rate”.

Your Whole Routine

Your Other Medicines and Supplements

Alternatives for the Same Use

Other Supplements for the Same Uses as Antineoplastons, and How They Mix With Nilutamide

Choosing a supplement while you take Nilutamide? Pick what you use Antineoplastons for to see other options studied for it, and whether each has a documented interaction with Nilutamide.

What do you take Antineoplastons for?

For Prostate Cancer

None of them has a documented interaction with Nilutamide.

3 other supplements have at least some evidence of a benefit for prostate cancer. Antineoplastons itself is graded for it.

  • Lycopene Graded No Known Interaction
  • Strontium Graded No Known Interaction
  • Sulforaphane Graded No Known Interaction

For Colorectal Cancer

None of them has a documented interaction with Nilutamide.

2 other supplements have at least some evidence of a benefit for colorectal cancer. Antineoplastons itself is graded for it.

The grades come from the Natural Medicines database and describe the research so far, not a recommendation, and none of these supplements replaces a prescribed medicine.

Everything Else You Take

See Every Supplement That Interacts With Nilutamide

Take other supplements too? 50 supplements have a documented interaction with Nilutamide, each explained on its page.

By severity: 1 major, 36 moderate and 13 minor.

The Most Serious There Right Now:

Open the Nilutamide interaction pageEvery supplement checked against Nilutamide, ranked by severity

Get to Know Each One

About Antineoplastons and Nilutamide

Supplement

About Antineoplastons

Antineoplastons are synthetic peptide and amino acid compounds promoted as an alternative cancer treatment, but they are not approved by the FDA and high-quality clinical evidence supporting their effectiveness is lacking. Most studies have been conducted by their developer and have not been independently confirmed. If you are considering them, talk with your oncologist first, and never replace proven cancer treatment with an unproven one.

Full Antineoplastons guide: uses, dosage, safety and every interaction
Safety at a Glance

How Antineoplastons Is Rated

  • Antineoplastons Overall

    Use caution

    Not FDA-approved; effectiveness is unproven and side effects can be serious, especially at high doses.

  • Pregnancy

    Avoid

    There is no reliable safety data, so use during pregnancy should be avoided.

  • Breastfeeding

    Avoid

    Safety while breastfeeding is unknown, so it should be avoided.

Medication

About Nilutamide

Brand names: Nilandron, Anandron

Nilutamide tablets are used together with surgical castration (removal of the testicles) to treat metastatic prostate cancer — prostate cancer that has spread to other parts of the body (Stage D2). It is not used alone; it works as part of this combined treatment approach.

Nilutamide: uses, dosage and side effects Nilutamide: interactions with other drugs Taking more than these two? Check Antineoplastons and Nilutamide with everything else you take Nilutamide NDC codes and packages

More to Explore

More Pairs and Interactions to Check

Keep Checking

Other Drugs & Antineoplastons

Browse every other medication we’ve checked against Antineoplastons — both the ones with a known interaction and the ones without. Select any drug for the full detail.

0Major
0Moderate
0Minor
2,829No known interaction
No Interaction 2,829 drugs checked — show the list

We also checked Antineoplastons against these medications and found no known interaction in our sources. Open any page to confirm.

Showing 60 of the 2,829 medications checked with no known interaction, the most looked-up first — see the full Antineoplastons list.

How Much People Look This Up

Where Antineoplastons and Nilutamide Sit Against Everything Else

Out of every supplement and medication people look up on HelloPharmacist, here is where these two land this week — and which way each has been moving.

Supplement Antineoplastons
Steady interest

#1,286 of 1,458 supplements looked up here in the last 7 days

29 days ago today
Medication Nilutamide
Steady interest

#2,570 of 2,830 medications looked up here in the last 7 days

29 days ago today

A rank of lookups on this site, not of how often either one is used. It counts every visit, automated ones included, and identifies no one.

Questions and Sources

Common Questions and Where This Comes From

Pharmacist Counseling Corner

Taking Antineoplastons and Nilutamide Together: Common Questions

Can you take Antineoplastons with Nilutamide?
We do not list a known interaction between Antineoplastons and Nilutamide. That does not guarantee the combination is risk-free, so confirm with your pharmacist or doctor — especially if you take other medications or have a health condition.
Can you take Antineoplastons with Nilandron?
Nilandron is a brand name of nilutamide, and so is Anandron, so the answer is the same as for nilutamide. We do not list a known interaction between Antineoplastons and Nilutamide. Everything on this page applies to Nilandron too.
Do Antineoplastons and Nilutamide have any of the same side effects?
Yes — our sources link each of them separately to 10 of the same effects. That is not a documented interaction, but taken together the same side effect from two sources might be more likely or stronger; no study of the two together says by how much. And if one of those effects turns up, it can be harder to tell which one is behind it. They are listed on this page with the source behind each.
Are Antineoplastons and Nilutamide used for the same thing?
They overlap in purpose, which usually means the real question is whether you need both rather than whether they are safe together. This page lists the shared uses and how strong the evidence is for Antineoplastons in each. That is a conversation for your prescriber, especially if Nilutamide is being adjusted to a target.
Do other supplements studied for prostate cancer interact with Nilutamide?
None of the 3 other supplements the Natural Medicines database grades as having some evidence of a benefit for prostate cancer has a documented interaction with Nilutamide. A grade is the research so far, not a recommendation, and no known interaction is not proof of safety; ask your pharmacist before adding one.
Does Nilutamide interact with any supplements?
Yes. Nilutamide has documented interactions with 50 supplements in our database — Antineoplastons is not one of them. The Nilutamide interaction page linked on this page lists every one, ranked by severity.

Written and reviewed by the HelloPharmacist Editorial Team. Our editorial policy

Evidence & Sources

References Cited on This Page

The 17 references the cards above cite, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.

Show the 17 references
  1. 20101. Burzynski SR, Mohabbat MO, Burzynski B. Human toxicology studies on oral formulation of Antineoplaston A10. Drugs Exp Clin Res 1984;10(12):891-909.
  2. 20102. Burzynski SR, Kubove E, Burzynski B. Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1. Drugs Exp Clin Res 1990;16(7):361-369.
  3. 25593. Buckner JC, Malkin MG, Reed E, et al. Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc 1999;74(2):137-145. PubMed
  4. 25601. Burzynski SR, Conde AB, Peters A, et al. A retrospective study of antineoplastons A10 and AS2-1 in primary brain tumors. Clin Drug Invest 1999;18(1):1-10.
  5. 25603. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 2003;4(2):91-101. PubMed
  6. 25604. Tsuda H, Hara H, Eriguchi N, et al. Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients. Kurume Med J 1995;42(4):241-249. PubMed
  7. 25607. Burzynski SR, Kubove E. Phase I clinical studies of antineoplaston A3 injections. Drugs Exp Clin Res 1987;13 Suppl 1:17-29.
  8. 25608. Burzynski SR, Kubove E, Burzynski B. Phase I clinical studies of antineoplaston A5 injections. Drugs Exp Clin Res 1987;13 Suppl 1:37-43.
  9. 25610. Burzynski SR, Weaver RA, Lewy RI, et al. Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report. Drugs R D 2004;5(6):315-326. PubMed
  10. 25611. Burzynski SR, Weaver RA, Janicki T, et al. Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1. Integr Cancer Ther 2005;4(2):168-177. PubMed
  11. 25619. Burzynski SR, Burzynski B, Mohabbat MO. Toxicology studies on antineoplaston AS2-1 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:25-35.
  12. 25620. Burzynski SR, Kubove E. Toxicology studies on antineoplaston A10 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:47-55.
  13. 25621. Burzynski SR, Kubove E. Initial clinical study with antineoplaston A2 injections in cancer patients with five years' follow-up. Drugs Exp Clin Res 1987;13 Suppl 1:1-11.
  14. 25622. Burzynski SR, Kubove E, Burzynski B. Phase I clinical studies of antineoplaston A5 injections. Drugs Exp Clin Res 1987;13 Suppl 1:37-43.
  15. 25623. Kumabe T, Tsuda H, Uchida M, et al. Antineoplaston treatment for advanced hepatocellular carcinoma. Oncol Rep 1998;5(6):1363-1367. PubMed
  16. 25624. Burzynski SR. Toxicology studies on antineoplaston AS2-5 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:17-24.
  17. 99814. Burzynski SR, Janicki TJ, Weaver RA, Burzynski B. Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma. Integr Cancer Ther. 2006 Mar;5(1):40-7. PubMed

All 20 references behind our Antineoplastons records are listed in the Antineoplastons guide.

Medication overviews come from MedlinePlus (NIH); supplement label data from the NIH Dietary Supplement Label Database. Content is reviewed by the HelloPharmacist Editorial Team. See our data sources and editorial standards.

Where Does Our Data Come From?
  • Source: the Natural Medicines (TRC Healthcare) clinical database — the evidence-graded professional reference for herb & supplement interactions.
  • Citation library: 105,612 references behind our interaction content, 67,053 of them resolved to verified PubMed/DOI sources. See the references behind this page ↓
  • Freshness: we automatically re-check this combination every week — this pair was last verified November 22, 2026. The Antineoplastons and Nilutamide records this page draws on were last updated July 10, 2026.
Data structure & sourcing designed and verified by .
Rating Key

What Our Interaction Ratings Mean

No interaction is on record for this pair. The other supplements and medicines on this page carry a severity rating: how serious an interaction between them is.

See what each severity means

Severity: How Serious Is It?

How clinically significant the interaction is: how much it could affect your health or your treatment.

  • MajorClinically significant. Best to avoid the combination, or use only under close professional supervision.
  • ModerateBe cautious. The combination may call for monitoring, timing changes, or a dose adjustment.
  • MinorLimited clinical concern, but still worth being aware of and mentioning to your pharmacist.
  • No Known InteractionNo documented interaction in our sources.

Still Have a Question About Antineoplastons and Nilutamide?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.